Pfizer-BioNTech’s COVID-19 shot found to be effective in kids under 5

By Nikita Chaurasia  | Date: 2022-08-24

Pfizer-BioNTech’s COVID-19 shot found to be effective in kids under 5

Pfizer Inc. and BioNTech SE reported that its COVID-19 vaccine is 73.2% effective among kids aged between 6 months to 4 years. The development comes two months after the vaccine was rolled out in the United States for this age group.

Moreover, the data showed that the vaccine shots generated an immunological response that was similar to that seen in older age groups.

The study that involved 10 symptomatic COVID-19 cases revealed that the vaccine had an 80.3% effectiveness rate. However, experts warned this was just preliminary data due to a low number of symptomatic cases.

Notably, the latest update involved 13 children who had COVID-19 and were studied seven days after receiving a third dose of the Pfizer-BioNTech Coronavirus vaccine, comparable to 21 cases among those who got a placebo. Most of the cases were caused by the Omicron BA.2 variant, which was highly prevalent in March and April of 2022 when the study was conducted.

Pfizer declared that pediatric trials for an Omicron-adapted vaccine will begin in the fall and that it would work with regulators to determine the data required for approval.

Pfizer and BioNTech also stated that they had filed an application seeking U.S. authorization for a bivalent vaccination targeting the BA.4/BA.5 subvariants of Omicron for children under the age of 12 as well as a booster dose for those 12 & above.

The recent data contains pre-clinical and manufacturing information for their bivalent COVID-19 vaccine that was modified for Omicron BA.4/BA.5 as well as data from research on their bivalent Omicron BA.1-adapted vaccine. Once the FDA grants an emergency use authorization (EUA), Pfizer-BioNTech will be prepared to ship dosages of the Omicron BA.4/BA.5-adapted bivalent boosters.

It is worth noting that Pfizer inked a new USD 3.2 billion worth contract with the U.S. government in June of this year, to provide 105 million doses, which also includes its Omicron-specific COVID-19 vaccines.

Source Credits:

https://www.business-standard.com/article/international/pfizer-s-covid-vaccine-73-2-effective-in-kids-under-5-shows-new-data-122082301085_1.html

About Author

Nikita Chaurasia     aeresearch.net

Nikita Chaurasia

An accomplished professional in the field of content development, playing with words comes naturally to Nikita Chaurasia. After completing her post-graduate MBA degree in Advertising and PR, Nikita worked across numerous content-driven verticals, undertaking diverse r...

Read More >>

More News By Nikita Chaurasia

Swiftly achieves Unicorn status with $100M Series C led by BRV Capital

Swiftly achieves Unicorn status with $100M Series C led by BRV Capital

By Nikita Chaurasia

Swiftly Systems has reportedly achieved unicorn status, securing in funding through a Series C round. The prominent BRV Capital Management led this funding initiative. According to the earlier reports, Swiftly was adopted by hundreds of consumer b...

Rainforest nations unify to demand cash for climate & biodiversity preservation

Rainforest nations unify to demand cash for climate & biodiversity preservation

By Nikita Chaurasia

As per the reports, twelve nations with rainforests united to establish a collective initiative aiming to address climate change and safeguard biodiversity at summit held in Brazil. The declaration, titled "United for Our Forests," emerged ...

AI Chatbot, Llama 2, unveiled by Meta for commercial use via Microsoft

AI Chatbot, Llama 2, unveiled by Meta for commercial use via Microsoft

By Nikita Chaurasia

Meta Platforms has recently introduced Llama 2, an artificial intelligence large language model, for commercial use in collaboration with major cloud providers like Microsoft. Instead of charging for access or usage, Meta aims to share the model with...

Moderna signs agreement to explore mRNA medicines in China

Moderna signs agreement to explore mRNA medicines in China

By Nikita Chaurasia

Moderna Inc, a leading vaccine manufacturer, reportedly announced on Wednesday that it has entered into a memorandum of understanding (MoU) and a land collaboration agreement aimed at exploring opportunities for researching, developing, and producing...

Nike and Epic Games collaborate to launch Airphoria NFT in Fortnite

Nike and Epic Games collaborate to launch Airphoria NFT in Fortnite

By Nikita Chaurasia

The American footwear design & manufacturing company, Nike and Epic Games, the creators of the popular online game Fortnite, have joined forces in an exciting new collaboration. The partnership aims to bring about a groundbreaking change in the d...